+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Doxorubicin"

Soft Tissue Sarcoma Market Report 2026 - Product Thumbnail Image

Soft Tissue Sarcoma Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Injectable Cytotoxic Drugs Market Report 2026 - Product Thumbnail Image

Injectable Cytotoxic Drugs Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Gastric Cancer Drugs Market Report 2026 - Product Thumbnail Image

Gastric Cancer Drugs Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
From
From
Sarcoma Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Sarcoma Therapeutics - Global Strategic Business Report

  • Report
  • May 2026
  • 180 Pages
  • Global
From
Soft Tissue Sarcoma - Global Strategic Business Report - Product Thumbnail Image

Soft Tissue Sarcoma - Global Strategic Business Report

  • Report
  • May 2026
  • 282 Pages
  • Global
From
From
Antibody Drug Conjugates - Competitive Landscape, 2026 - Product Thumbnail Image

Antibody Drug Conjugates - Competitive Landscape, 2026

  • Report
  • January 2026
  • 450 Pages
  • Global
From
CTLA-4 Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

CTLA-4 Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 220 Pages
  • Global
From
From
From
From
From
Liposomal Doxorubicin Market Report and Forecast 2025-2034 - Product Thumbnail Image

Liposomal Doxorubicin Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
From
Osteosarcoma Pipeline Analysis Report 2025 - Product Thumbnail Image

Osteosarcoma Pipeline Analysis Report 2025

  • Report
  • June 2025
  • 200 Pages
  • Global
From
B Cell Non-Hodgkin Lymphoma Pipeline Analysis Report 2025 - Product Thumbnail Image

B Cell Non-Hodgkin Lymphoma Pipeline Analysis Report 2025

  • Report
  • June 2025
  • 200 Pages
  • Global
From
Ovarian Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Ovarian Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Loading Indicator

Doxorubicin is an oncology drug used to treat a variety of cancers, including leukemia, lymphoma, and breast, ovarian, and bladder cancer. It is a type of anthracycline antibiotic, derived from Streptomyces peucetius, and works by interfering with the growth of cancer cells. It is administered intravenously, and is often used in combination with other drugs. Doxorubicin is one of the most widely used chemotherapy drugs, and is often used in combination with other drugs to treat a variety of cancers. It is also used to treat Kaposi's sarcoma, a type of skin cancer. Side effects of doxorubicin include nausea, vomiting, hair loss, and an increased risk of infection. The doxorubicin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more